Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | RARB | P10826 | 8/20 | 0.41 |
| ▸ | RARA | P10276 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | RARG | P13631 | 1/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | MTOR | P42345 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16024611 | 1.00 | HSD11B1 (0.41) | HSD11B1RARBRARACNR1CNR2 | |
| SCHEMBL16024627 | 0.99 | HSD11B1 (0.40) | HSD11B1RARBRARACNR1CNR2 | |
| SCHEMBL16024631 | 0.99 | HSD11B1 (0.40) | HSD11B1RARBRARACNR1CNR2 | |
| SCHEMBL16981570 | 0.90 | CNR1 (0.40) | HSD11B1RARBRARACNR1CNR2 | |
| SCHEMBL16807672 | 0.89 | SPHK2 (0.41) | CNR1CNR2SPHK1 | |
| SCHEMBL16024615 | 0.88 | ESR1 (0.42) | ALDH1A1HSD17B10 | |
| SCHEMBL15223418 | 0.88 | ESR1 (0.42) | ALDH1A1HSD17B10 | |
| SCHEMBL18352172 | 0.88 | ESR1 (0.42) | ALDH1A1HSD17B10 | |
| SCHEMBL15223412 | 0.88 | ESR1 (0.42) | ALDH1A1HSD17B10 | |
| SCHEMBL15223469 | 0.88 | ESR1 (0.42) | ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9853225-B2 | Chalcogen-containing organic compound and a use thereof | JNC CORPORATION (JP) | 2017-12-26 | — | — | US | disclosed |
| US-20160013425-A1 | A CHALCOGEN-CONTAINING ORGANIC COMPOUND AND A USE THEREOF | PI-CRYSTAL INC. (JP) | 2016-01-14 | — | — | US | disclosed |
| WO-2014136827-A1 | CHALCOGEN-CONTAINING ORGANIC COMPOUND AND USE THEREFOR | JNC株式会社 (JP) | 2014-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160013425-A1 | A CHALCOGEN-CONTAINING ORGANIC COMPOUND AND A USE THEREOF | SCO2, SOD1, GPX1 | HSD11B1 244/4885RARB 2481/4885RARA 2393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.